Roche provides update on splicing modifier RG7916
Patients who participated in the Moonfish study will have the opportunity to enrol in an open label study with RG7916, if they fulfil study criteria and wish to participate. These patients will be contacted by their clinical trial site to update them on this development.
RG7916 is a splicing modifier, a compound which works by increasing the amount of SMN protein made by the SMN2 gene.
Please read the full community statement.